AI-enhanced ECGs may soon assess overall health

By

Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients.

An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical activity of a person’s heart.

A recent paper in the journal Circulation: Arrhythmia and Electrophysiology, describes how the team developed an artificial intelligence (AI) tool to predict sex and estimate age from ECG data. If you want to know more about this news, click here.

Posted in News, Science, Technology.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    10 octubre, 2019

    Deep brain stimulation can be effective for severe depression

    Researchers who monitored people with deep brain stimulation implants for 8 years suggest that the treatment can benefit those with severe depression. Regulators in the United States have already approved deep brain stimulation for the treatment of Parkinson’s disease, epilepsy, essential tremor, and obsessive-compulsive disorder. The treatment involves implanting wires into the brain and a stimulator in the chest …

  •
    10 octubre, 2019

    ‘Electronic tongues’ may help diagnose early stage bladder cancer

    New research presents a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. In a quest to find a better way of diagnosing bladder cancer, Spain-based researchers from the Polytechnic University of Valencia (UPV), the La Fe …

  •
    18 junio, 2019

    More than 1 million Class I medical device units recalled in Q1

    For the third consecutive quarter, more than one million Class I units were recalled during 2019’s Q1. If you want to read more about this news click here. If you want to read more about this news click here.

  •
    10 octubre, 2019

    Medtronic announces Infuse spine trial

    Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, …